This invention relates to the alleviation of symptoms of Th2-like cytokine mediated disorders, such as allergy, asthma, and to hyperinflammatory responses in the respiratory tract to infectious diseases and parasitic infections, including tuberculosis, schistosomiasis, leishmania, and filariasis.
This invention claims a variety of methods and uses of a chimeric molecule comprising a toxic moiety and a targeting moiety that specificall... More ...
Technologies Available for Licensing from Non-Profit Institutions
